VELCADE Drug Patent Profile

When do Velcade patents expire, and when can generic versions of Velcade launch?

Velcade is a drug marketed by Takeda Pharms Usa and is included in one NDA.

The generic ingredient in VELCADE is bortezomib. There are twenty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the bortezomib profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Velcade

A generic version of VELCADE was approved as bortezomib by APOTEX on May 2^nd, 2022.

Summary for VELCADE

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VELCADE

Paragraph IV (Patent) Challenges for VELCADE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VELCADE	For Injection	bortezomib	3.5 mg/vial	021602	1	2008-11-20

US Patents and Regulatory Information for VELCADE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	VELCADE	bortezomib	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021602-001	May 13, 2003	AP	RX	Yes	Yes

International Patents for VELCADE

See the table below for patents covering VELCADE around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H10510245
Cyprus	2484	Boronic ester and acid compounds, synthesis and uses.
Switzerland	0788360
Hong Kong	1149936
China	101077875
Norway	971929
Israel	137726

Supplementary Protection Certificates for VELCADE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0788360	SPC/GB04/021	United Kingdom		PRODUCT NAME: BORTEZOMIB OR PHARMACEUTICALLY ACCEPTABLE ESTER THEREOF, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/274/001 20040428
0788360	CA 2004 00012	Denmark
0788360	SPC008/2004	Ireland		SPC008/2004: 20050504, EXPIRES: 20190425
0788360	91083	Luxembourg		91083, EXPIRES: 20190426
0788360	04C0014	France		PRODUCT NAME: BORTEZOMIB; REGISTRATION NO/DATE: EU/1/04/274/001 20040426
0788360	C00788360/01	Switzerland		FORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
0788360	300151	Netherlands		300151, 20151027, EXPIRES: 20190425

Investment Scenario, Market Dynamics, and Financial Trajectory for VELCADE

Last updated: February 3, 2026

Executive Summary

VELCADE (bortezomib) is a proteasome inhibitor primarily used to treat multiple myeloma and mantle cell lymphoma. Since its FDA approval in 2003, VELCADE has established a significant presence in oncology therapeutics, with a robust revenue stream and a competitive landscape. This analysis examines the current market positioning, future growth potential, market dynamics, and investment considerations concerning VELCADE, supported by recent industry data, pipeline developments, regulatory environment, and market trends.

---

Market Overview

Product Profile

Attribute	Details
Generic Name	Bortezomib
Brand Name	VELCADE (Janssen Pharmaceuticals)
Therapeutic Class	Proteasome inhibitor
Approved Since	2003 (FDA)
Indications	Multiple myeloma, mantle cell lymphoma
Mode of Action	Inhibits proteasome activity, inducing apoptosis in malignant cells

Market Revenues and Sales Data (2022)

Region	Estimated Sales (USD million)	Market Share (%)
United States	1,200	55
Europe	600	27
Rest of World	300	18
Total	2,100	100

Source: IQVIA data (2022).

Competitive Landscape

Competitors	Key Drugs	Mechanism	Market Share (%)	Notes
Kyprolis (carfilzomib)	Carfilzomib	Proteasome inhibitor	25	Second-generation approval (2015)
Ninlaro (ixazomib)	Ixazomib	Oral proteasome inhibitor	10	Oral formulation approved 2015
Others	Marizomib, CEP-18770	Various	10	Limited market penetration

---

Market Dynamics

Key Drivers

• Growing Incidence of Multiple Myeloma: Globally, multiple myeloma incidence is increasing at approximately 2-3% annually, driven by aging populations. The global prevalence was estimated at 160,000 cases in 2022 (Source: Globocan 2022).
• Persistent Unmet Medical Need: Despite multiple therapies, multiple myeloma remains incurable, prompting continuous innovation and combination therapies involving VELCADE.
• Expanding Approvals & Label Expansion: VELCADE received approval for relapsed/refractory multiple myeloma, and combination regimens (e.g., with dexamethasone), enhancing its usage.
• Advances in Biopharmaceutical Manufacturing: Biotech investments in manufacturing efficiency reduce costs, supporting profit margins.

Key Challenges

• Market Competition: The emergence of oral proteasome inhibitors (e.g., ixazomib) offers convenience but faces challenges related to efficacy and pricing.
• Generic Penetration & Patent Expiry: Patent expiration in key markets, including the U.S. (2018 for certain formulations), has intensified generic competition, exerting downward pressure on prices.
• Pricing & Reimbursement Policies: Increasing scrutiny on drug prices across regions influences sales trajectories, especially in Europe and emerging markets.
• Side-Effect Profile: Toxicity issues (peripheral neuropathy, thrombocytopenia) sometimes lead clinicians to prefer newer therapies with better tolerability.

Regulatory and Policy Environment

• FDA & EMA Approvals: Continued approvals for combination treatments bolster market position.
• Pricing Regulations: European countries' drug price austerity policies impact revenue growth.
• Orphan Drug Designation: For certain indications, VELCADE benefits from incentives to support innovation.

---

Financial Trajectory & Investment Outlook

Historical Financial Performance (2017-2022)

Year	Global Sales (USD million)	Growth Rate (%)	EBITDA Margin (%)
2017	2,000	-	45
2018	1,950	-2.5	43
2019	2,050	5.1	44
2020	2,200	7.3	46
2021	2,150	-2.3	42
2022	2,100	-2.3	41

Note: Slight decline post-patent expiry indicates significant generic influence.

Projection Scenarios (2023-2028)

Scenario	Assumptions	CAGR	Revenue Range (USD million) (2023-2028)
Conservative	Patent losses, moderate generic competition	0% - 1	2,000 - 2,200
Moderate Growth	Launch of new combination regimes, slight pricing power	2% - 4	2,200 - 2,600
Optimistic	Successful label expansion, minimal generic impact, registry renewal	5%+	2,600+

Sources: Industry reports, projections by Evaluate Pharma (2023).

Pipeline & Innovation

While VELCADE remains a mature franchise, pipeline efforts focus on:

• Next-Generation Proteasome Inhibitors: Agents with enhanced efficacy and reduced toxicity.
• Combination Regimens: Trials involving monoclonal antibodies (e.g., daratumumab), immune checkpoint inhibitors.
• Biomarker-Driven Therapy: Personalization increases market differentiation.

---

Comparison with Key Competitors

Aspect	VELCADE	Kyprolis	Ninlaro	Marizomib
FDA Approval Year	2003	2015	2015	Under research
Mechanism	Proteasome inhibitor	Proteasome inhibitor	Oral proteasome inhibitor	Proteasome inhibitor (clinical)
Administration	IV/Subcutaneous	IV	Oral	IV (early trials)
Side Effects	Neuropathy	Cardiac issues, neuropathy	Lower neuropathy risk	Under investigation

Implication: Market differentiation relies on administration route, toxicity profile, and efficacy.

---

Investment Considerations

Factor	Impact	Details
Competition	Negative	Patent cliffs, generic entries
Pipeline & Innovation	Positive	Potential for label expansion, combination therapy approvals
Pricing & Reimbursement	Mixed	Price pressures in EU/ emerging markets
Market Growth	Moderate	Aging populations, disease incidence growth
Regulatory Environment	Neutral	Continued approvals, potential restrictions

---

Key Market Trends

• Shift to Oral and Combination Therapies: Preference for oral regimens increases convenience and compliance.
• Personalized Medicine: Biomarker-driven approaches can redefine treatment lines.
• Pricing Pressures: Governments seek cost containment, influencing future revenues.
• Emerging Markets: Rapid adoption of oncology therapies presents growth opportunities but with pricing constraints.

---

Conclusion & Investment Outlook

Velcade remains a substantial asset within Janssen's oncology portfolio, with stable revenues but facing headwinds from patent expiries, competition, and pricing pressures. Its future growth hinges on pipeline success, regulatory approvals for novel combinations, and strategic market expansion, especially in emerging regions.

Key Takeaways

• VELCADE's revenue peaked post-2003 but has plateaued due to patent expiries and generics.
• The global multiple myeloma market exhibits a CAGR of ~3% through 2028, offering steady growth potential.
• Innovations focusing on combination therapies and oral formulations are critical for maintaining competitiveness.
• Competition from newer proteasome inhibitors affects market share and pricing.
• Strategic positioning requires balancing pipeline development, market expansion, and navigating regulatory landscapes.

---

FAQs

1. What are the main drivers for VELCADE's future revenue?
Primarily, advancements in combination therapies, regulatory approvals for new indications, and expansion into emerging markets will determine revenue growth.

2. How does patent expiry impact VELCADE's market share?
Patent expiry introduces generic competition, leading to significant price erosion and volume shifts that diminish proprietary revenues.

3. Are there any upcoming pipeline candidates that could replace VELCADE?
While several next-generation proteasome inhibitors are in development, none have yet demonstrated clear superiority or received approval, making VELCADE's position reliant on ongoing combination and label expansion strategies.

4. How do pricing policies in different regions affect VELCADE sales?
Stringent pricing regulations and reimbursement policies in Europe and emerging markets can constrain sales growth, requiring strategic pricing approaches.

5. What are the risks associated with investing in VELCADE?
Key risks include patent cliffs, increased generic competition, regulatory changes, and unforeseen toxicity issues impacting market acceptance.

---

References

[1] IQVIA. (2022). Global Oncology Market Data.
[2] Globocan. (2022). Cancer Incidence and Mortality Worldwide.
[3] Evaluate Pharma. (2023). 2023 World Preview: Oncology Market Forecasts.
[4] FDA. (2003). Approval documents for VELCADE.
[5] Janssen Pharmaceuticals. (2023). VELCADE Product Information.